Island Pharmaceuticals Jumps 47% on Uganda Ebola Approval for Galidesivir
Updated
Updated · Bloomberg · Jul 7
Island Pharmaceuticals Jumps 47% on Uganda Ebola Approval for Galidesivir
2 articles · Updated · Bloomberg · Jul 7
Summary
Island Pharmaceuticals shares surged as much as 47% in Sydney after the company said galidesivir won regulatory and ethics clearance for emergency use against the Bundibugyo strain of Ebola in Uganda.
Galidesivir is an intravenous antiviral designed to block viral replication, and Island said it is expected to become available later this year through a World Health Organization emergency-use program.
The stock was still up 30% at A$0.48 by 10:51 a.m. in Sydney after earlier touching A$0.55, its highest intraday level since December 2025.
Beyond Ebola, could this approval position galidesivir as a lucrative asset for US biodefense against the deadly Marburg virus?
A cure exists, but will deep-seated distrust and disinformation in Ebola-stricken regions prevent it from saving lives?
Uganda Approves Emergency Use of Galidesivir for Dual Ebola and Marburg Outbreaks: First Real-World Deployment of Broad-Spectrum Antiviral Under MEURI Protocol
Overview
Uganda is facing a severe public health emergency due to a growing Bundibugyo Ebola outbreak and a fatal Marburg virus case, highlighting an urgent medical need as there are no approved treatments for these deadly viruses. In response, Island Pharmaceuticals Ltd has received approval for the compassionate use of its investigational antiviral, Galidesivir, in Uganda. Galidesivir is being advanced as a potential treatment for high-consequence pathogens like Ebola and Marburg. This emergency use aims to provide immediate help to patients while collecting important safety and clinical data, offering hope in a critical situation where treatment options are lacking.